BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30223465)

  • 1. TOP2B: The First Thirty Years.
    Austin CA; Lee KC; Swan RL; Khazeem MM; Manville CM; Cridland P; Treumann A; Porter A; Morris NJ; Cowell IG
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
    Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
    BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
    Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
    Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.
    Chikamori K; Grozav AG; Kozuki T; Grabowski D; Ganapathi R; Ganapathi MK
    Curr Cancer Drug Targets; 2010 Nov; 10(7):758-71. PubMed ID: 20578986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.
    Gilroy KL; Austin CA
    PLoS One; 2011 Feb; 6(2):e14693. PubMed ID: 21358820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ.
    Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE
    Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
    Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
    Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
    Lok CN; Lang AJ; Mirski SE; Cole SP
    Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase IIβ and its role in different biological contexts.
    Bollimpelli VS; Dholaniya PS; Kondapi AK
    Arch Biochem Biophys; 2017 Nov; 633():78-84. PubMed ID: 28669856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
    Bergant K; Janezic M; Perdih A
    Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.
    Pogorelčnik B; Perdih A; Solmajer T
    Curr Med Chem; 2013; 20(5):694-709. PubMed ID: 23210851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
    Swan RL; Cowell IG; Austin CA
    Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eukaryotic DNA topoisomerase II beta.
    Austin CA; Marsh KL
    Bioessays; 1998 Mar; 20(3):215-26. PubMed ID: 9631649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
    Fortune JM; Osheroff N
    Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulated activity of human topoisomerases IIalpha and IIbeta on RNA-containing substrates.
    Wang Y; Knudsen BR; Bjergbaek L; Westergaard O; Andersen AH
    J Biol Chem; 1999 Aug; 274(32):22839-46. PubMed ID: 10428869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of new ATP-competitive inhibitors of human DNA topoisomerase IIα through screening of bacterial topoisomerase inhibitors.
    Skok Ž; Durcik M; Gramec Skledar D; Barančoková M; Peterlin Mašič L; Tomašič T; Zega A; Kikelj D; Zidar N; Ilaš J
    Bioorg Chem; 2020 Sep; 102():104049. PubMed ID: 32688116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.